GeneDx Holdings Corp.
Market Cap
$2.21B
P/E Ratio
-103.42
EPS
$-0.73
Dividend Yield
0.00%
52-Week Range
$55.17 — $170.87
Volume
383.26K
Avg Volume
710.67K
Beta
2.15
P/E (TTM)
-103.42
Forward P/E
134.27
PEG Ratio
0.11
P/S (TTM)
6.09
P/B (TTM)
7.75
P/FCF
323.36
EV/EBITDA
-8863.24x
EV/Sales
—
ROE (TTM)
-0.07%
ROA (TTM)
-0.04%
ROIC
-0.01%
Gross Margin
0.68%
Operating Margin
-0.03%
Net Margin
-0.07%
Debt/Equity
0.49
Current Ratio
2.46
EPS Growth (YoY)
+0.14%
Revenue Growth (YoY)
+0.43%
EPS Growth (3Y)
+0.63%
EPS Growth (5Y)
-1.23%
Sales Growth (3Y)
+0.16%
Sales Growth (5Y)
+0.11%
EPS Est (This Year)
$0.56
EPS Est (Next Year)
$1.96
Dividend Yield
—
Annual Dividend
—
Payout Ratio
0.00%
Frequency
—
Ex-Dividend Date
—
Cash/Share
$6.37
Buy
1 = Strong Buy, 5 = Strong Sell
Price Target Range
Consensus Target: $173.75(130.1% upside)
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
-11344
Outstanding Shares
28.90M
Float
25.35M
Free Float %
87.71%
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Country
US
Exchange
NASDAQ
IPO Date
2020-11-04
Employees
1000
CEO
Katherine A. Stueland
Index Membership
—
Website
http://www.genedx.com
GeneDx Holdings Corp. (WGS) is a healthcare company in the medical - healthcare information services industry listed on the NASDAQ. With a market capitalization of $2.21B, a P/E ratio of -103.42, WGS is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare WGS against other stocks using dozens of fundamental and technical filters.
GeneDx Holdings Corp. (WGS) has a trailing twelve-month (TTM) P/E ratio of -103.42. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, GeneDx Holdings Corp. (WGS) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
GeneDx Holdings Corp. (WGS) has a market capitalization of $2.21 billion, classifying it as a mid-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.
Wall Street analysts have a consensus "Buy" rating on GeneDx Holdings Corp. (WGS) with an average score of 2.00 on a 1-5 scale (1 = Strong Buy, 5 = Strong Sell). The consensus price target of $173.75 implies 130.1% upside from the current price.